==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

Th1143 details

Primary information
ID 1637
ThPP ID Th1143
Therapeutic Peptide/Protein Name Fibrinolysin aka plasmin
Sequence Fibrinolysin heavy chainDLLDDYVNTQGASLLSLSRKNLAGRS view full sequnce in fasta
Functional Classification Ic
Molecular Weight 88400
Chemical Formula C3848H5912N1096O1185S60
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life 24 hrs
Description Derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90 kDa. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27 kDa and contains the active center of fibrinolysin; the heavy chain has a molecular weight of approximately 57 kDa. It is used as a local healing ointment when combined with the enzyme deoxyribonuclease I (derived from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs deoxyribonuclease per gram. The ointment (Fibrolan) is marketed by Pfizer in a variety of countries is currently not approved in the USA.
Indication/Disease Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
Pharmacodynamics N.A.
Mechanism of Action Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue.
Toxicity N.A.
Metabolism local inactivation.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number US3234106
Date of Issue 13/03/66
Date of Expiry 13/03/86
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Elase
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://en.wikipedia.org/wiki/Fibrinolysin http://www.drugs.com/international/fibrinolysin.html
PubMed ID 6226244
3-D Structure Th1143 Heavy chianor (Download)Th1143 Light chian (View) or (Download) Th1191 Heavy chianor (Download)Th1191 Light chian (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1637
ThPP ID	Th1143
Therapeutic Peptide/Protein Name	Fibrinolysin aka plasmin
Sequence	Fibrinolysin heavy chainDLLDDYVNTQGASLLSLSRKNLAGRS view full sequnce in fasta
Functional Classification	Ic
Molecular Weight	88400
Chemical Formula	C3848H5912N1096O1185S60
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	24 hrs
Description	Derived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90 kDa. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27 kDa and contains the active center of fibrinolysin; the heavy chain has a molecular weight of approximately 57 kDa. It is used as a local healing ointment when combined with the enzyme deoxyribonuclease I (derived from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs deoxyribonuclease per gram. The ointment (Fibrolan) is marketed by Pfizer in a variety of countries is currently not approved in the USA.
Indication/Disease	Fibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
Pharmacodynamics	N.A.
Mechanism of Action	Fibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue.
Toxicity	N.A.
Metabolism	local inactivation.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	US3234106
Date of Issue	13/03/66
Date of Expiry	13/03/86
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Elase
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://en.wikipedia.org/wiki/Fibrinolysin http://www.drugs.com/international/fibrinolysin.html
PubMed ID	6226244
3-D Structure	Th1143 Heavy chianor (Download)Th1143 Light chian (View) or (Download)	Th1191 Heavy chianor (Download)Th1191 Light chian (View) or (Download)